Gilead Announces Intent to Submit New Drug Application for Filgotinib to U.S. Food and Drug Administration This Year

Gilead Sciences Inc. NASDAQ GILD today announced that at a recent preNew Drug Application NDA meeting with the U.S. Food and Drug Administration FDA the company provided an update about the investigational oral selective JAK1 inhibitor filgotinib. The comp...